S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)

Olema Pharmaceuticals (OLMA) SEC Filings & 10K Form

$13.87
-0.47 (-3.28%)
(As of 02/21/2024 ET)

Recent Olema Pharmaceuticals SEC Filings

DateFilerForm TypeView
02/14/2024
11:53 AM
Kynam Capital Management, LP (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2024
4:16 PM
Olema Pharmaceuticals (Filer)
Form 424B3
02/12/2024
11:21 AM
JANUS HENDERSON GROUP PLC (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13G/A
02/11/2024
11:15 PM
Olema Pharmaceuticals (Filer)
Form EFFECT
02/05/2024
4:30 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
4:30 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
4:30 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2024
4:30 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2024
4:00 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/01/2024
2:24 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/31/2024
1:58 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
4:25 PM
BlackRock Inc. (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13G
01/29/2024
6:30 AM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
6:30 AM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024
8:07 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
7:18 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2024
4:25 PM
Olema Pharmaceuticals (Filer)
Form 424B5
01/05/2024
4:26 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2024
4:30 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
5:30 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:55 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:55 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2023
3:19 PM
Asefaw Senai (Reporting)
Olema Pharmaceuticals (Issuer)
Paradigm BioCapital Advisors GP LLC (Reporting)
Paradigm Biocapital Advisors LP (Reporting)
Paradigm BioCapital International Fund Ltd. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/07/2023
7:30 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 3/A
12/07/2023
7:30 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
6:48 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2023
4:15 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/01/2023
4:15 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/30/2023
9:20 AM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/22/2023
6:00 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2023
6:00 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2023
6:00 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2023
6:00 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2023
6:00 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2023
2:25 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/22/2023
2:04 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/22/2023
2:12 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/22/2023
1:35 PM
Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/22/2023
1:42 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2023
2:11 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2023
2:16 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2023
1:49 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2023
1:52 PM
Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2023
4:30 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2023
8:39 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2023
3:53 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/02/2023
7:50 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2023
3:46 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/02/2023
3:21 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2023
3:49 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/31/2023
9:38 AM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2023
6:45 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/18/2023
3:46 PM
Olema Pharmaceuticals (Filer)
Form 8-K/A
10/17/2023
3:42 PM
Garland J. Scott (Reporting)
Olema Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/17/2023
3:43 PM
Garland J. Scott (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2023
6:33 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2023
6:17 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2023
10:05 AM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/21/2023
4:12 PM
Asefaw Senai (Reporting)
Olema Pharmaceuticals (Issuer)
Paradigm BioCapital Advisors GP LLC (Reporting)
Paradigm Biocapital Advisors LP (Reporting)
Paradigm BioCapital International Fund Ltd. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/14/2023
3:23 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13D/A
09/14/2023
3:25 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/14/2023
3:14 PM
Olema Pharmaceuticals (Filer)
Form D
Notice of Exempt Offering of Securities 
09/13/2023
4:22 PM
Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G/A
09/05/2023
8:08 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
3:05 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4/A
09/05/2023
12:42 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2023
6:39 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/16/2023
3:37 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/20/2023
11:22 AM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/18/2023
1:54 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2023
3:36 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/28/2023
3:40 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/27/2023
3:49 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/21/2023
6:14 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
Olema Pharmaceuticals (Issuer)
RAPPAPORT ANDREW (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
BUTITTA CYNTHIA M (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
Hrustanovic Gorjan (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
Horning Sandra (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
Larson Yi (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:00 PM
CLARK IAN T (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
3:31 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/14/2023
3:23 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/13/2023
3:28 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2023
4:53 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2023
4:30 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2023
4:58 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/07/2023
8:30 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2023
2:19 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2023
5:22 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2023
4:31 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2023
12:09 PM
Moriarty John B (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2023
8:24 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2023
3:25 PM
Olema Pharmaceuticals (Filer)
Form ARS
04/10/2023
3:33 PM
Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G
04/07/2023
3:30 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/29/2023
11:36 AM
Horn Kinney (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2023
3:51 PM
Olema Pharmaceuticals (Filer)
Form 424B5
03/09/2023
3:33 PM
Olema Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:OLMA) was last updated on 2/21/2024 by MarketBeat.com Staff